Document 1200
 DOCN  M94A1200
 TI    Immunotherapy with intravenous immunoglobulin G (IVIG) in HIV illness.
 DT    9412
 AU    Diaz Brito A; Feregrino Goyos M; Eid-Lidt G; Alvarado Diez R; Gallegos
       Perez H; Perez AI; Clinica ISI de Norteamerica, Mexico D.F., Mexico.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):186 (abstract no. PB0758). Unique
       Identifier : AIDSLINE ICA10/94371375
 AB    OBJECTIVES: We tried to evaluate the benefit of Intravenous
       Immunoglobulin G administration (IVIG)) in two situations of the HIV
       disease, the thrombocytopenic purpura and in the rescue therapy of
       highly severe malignant lymphoma under multiple chemotherapy as
       prevention of opportunistidc infections. METHODS: we studied 4 patients
       HIV positives. The first two had Non hodgkins lymphoma of severe
       malignancy degree and invasion of liver and spleen, with severe
       immunodeficiency with less than 50 CD4 and neutropenia until less than
       100 after the chemotherapy with multiple drugs: vincristina,
       cyclofosfamide, alexan, daunorrubicina, methotrexate, cis plantino, in
       various schemes designed by their oncologist in cycles during periods of
       each 2 weeks. They received treatment with IVIG 400 mg each kg of body
       weight i.v. after they received quemotherapy, and in presence of
       neutropenia. The patients received GMCSF and GCSF obviously. Another 2
       patients more stable with CD4 counts of 220 and 150 who went throungh
       thrombocytopenia with risk of bleeding (less than 20,000 bt mm3). They
       received each period of major thrombocytopenia 400 mg for each kg of
       body weight i.v. daily until correction of thrombocytopenia until more
       than 100,000 per mm3. A retrospective study was conducted of the
       evolution and results of IVIG therapy. RESULTS AND CONCLUSIONS: None of
       the patients subjected to chemotherapy suffered severe opportunistic
       infections during neutropenia. The number of platelets of the patients
       with thrombocytopenia purpura recovered to 100,000 with one treatment.
       We recommended IVIG treatment in these complications of HIV illness.
 DE    Antineoplastic Agents, Combined/THERAPEUTIC USE  Case Report
       Granulocyte Colony-Stimulating Factor/THERAPEUTIC USE
       Granulocyte-Macrophage Colony-Stimulating Factor/THERAPEUTIC USE  Human
       HIV Seropositivity/COMPLICATIONS/IMMUNOLOGY/*THERAPY  Immunoglobulins,
       Intravenous/*THERAPEUTIC USE  *Immunotherapy  Leukocyte Count  Lymphoma,
       Non-Hodgkin's/COMPLICATIONS/DRUG THERAPY  T4 Lymphocytes  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).